Travelers Companies (TRV) Expands Life Sciences Coverage, Is It Still Overvalued?
Travelers Companies expansion and recent bond issuance
Travelers Companies (TRV) recently completed the nationwide rollout of its Travelers Synergy product liability coverage for life sciences firms, while also issuing callable senior unsecured fixed rate notes due 2031 totaling about US$750 million.
See our latest analysis for Travelers Companies.
At a share price of US$374.36, Travelers Companies has had a mixed few days, with the 1-day share price return declining 0.43% and the 7-day share price return down 3.33%. However, the 30-day and year to date share price returns of 11.88% and 31.27% respectively, together with a 1-year total shareholder return of 47.23% and 5-year total shareholder return of 169.96%, indicate momentum has been building alongside recent product expansion and bond issuance.
If Travelers Companies' recent moves have you thinking about where else insurance related capital might flow next, it could be worth scanning 35 power grid technology and infrastructure stocks for potential beneficiaries of long term infrastructure and risk management themes.
After a sharp 1 year total return and a sizeable intrinsic value buffer indicated by current estimates, Travelers Companies now sits at an interesting crossroads. The key question is whether the recent run and new debt issue still leave enough upside relative to the risk taken.
Most Popular Narrative: 5.5% Overvalued
The most followed narrative currently places Travelers Companies' fair value at $354.71, which sits below the last close of $374.36 and frames the stock as slightly ahead of that estimate.
The analysts have a consensus price target of $354.71 for Travelers Companies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $430.0, and the most bearish reporting a price target of just $262.0.
Want to see what justifies paying above the consensus fair value? The narrative leans on shifting earnings, margins, and a richer future earnings multiple. The key is how those ingredients fit together in the model.
Result: Fair Value of $354.71 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story for Travelers Companies could shift quickly if catastrophe losses spike again, or if social inflation and competitive pressure squeeze underwriting margins more than expected.
Find out about the key risks to this Travelers Companies narrative.
Another View on Travelers Companies valuation
Analysts see Travelers Companies as about 5.5% above their $354.71 fair value estimate, yet the SWS DCF model tells a different story. On that approach, TRV at $374.36 sits roughly 51% below an estimated future cash flow value of $762.64. This paints a very different risk reward picture.
For a closer look at how that cash flow based estimate is built and what would need to hold true for it to make sense, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Travelers Companies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Unsure how to weigh the mixed sentiment around Travelers Companies right now? Take a closer look at the data, act promptly, and shape your own view with the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Travelers Companies?
Do not stop your research with Travelers Companies. Broaden your watchlist now using focused stock ideas that highlight quality, resilience, and income potential across the market.
- Target long term value by scanning companies that trade below their estimated worth and still show solid fundamentals through the 55 high quality undervalued stocks.
- Strengthen your portfolio foundation by focusing on businesses with robust finances using the solid balance sheet and fundamentals stocks screener (45 results).
- Turn steady cash payouts into a core part of your returns by reviewing income focused opportunities in the 9 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com